Previous 10 | Next 10 |
2023-12-04 06:55:43 ET More on Tenax Therapeutics Tenax falls as rally driven by IND clearance cools Tenax stock jumps after FDA greenlights studies for hypertension candidate Seeking Alpha’s Quant Rating on Tenax Therapeutics Historical earnings data ...
CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the app...
2023-11-14 14:48:39 ET More on Tenax Therapeutics Tenax stock jumps after FDA greenlights studies for hypertension candidate Seeking Alpha’s Quant Rating on Tenax Therapeutics Historical earnings data for Tenax Therapeutics Financial information for Te...
2023-11-13 12:36:46 ET Gainers: Tenax Therapeutics ( TENX ) +310% . Tivic Health Systems ( TIVC ) +71% . Montauk Renewables ( MNTK ) +28% . Sohu.com Ltd. ( SOHU ) +24% . INVO Bioscience ( INVO ) +26% . Direct Digital Holdings...
2023-11-13 12:21:16 ET DENVER, Colo., Nov. 13, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Tenax Therapeutics Inc (NASDAQ: TENX), RLX Technology Inc (NYSE: RLX), FREYR Battery (NYSE: FREY), Car...
2023-11-13 09:56:35 ET DENVER, Colo., Nov. 13, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Tenax Therapeutics Inc (NASDAQ: TENX), RLX Technology Inc (NYSE: RLX), FREYR Battery (NYSE: FREY), Tivic Heal...
First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study) FDA agreement that 6MWD will be the primary endpoint for both Phase 3 studies Phase 3 program designed to satisfy FDA’s request for subject drug exposure of 300 patients for 6 months, ...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...
Verbund AG ADR (OEZVY) is expected to report for Q2 2023 Adtran Networks SE (ADVOF) is expected to report for Q2 2023 OMV AG (OMVJF) is expected to report $1.66 for Q2 2023 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 Minim Inc (MINM) is expected to r...
News, Short Squeeze, Breakout and More Instantly...
Tenax Therapeutics Inc. Company Name:
TENX Stock Symbol:
NASDAQ Market:
Tenax Therapeutics Inc. Website:
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent ...
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF Provides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond ...